JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $667,000 | +172.2% | 30,053 | +131.8% | 0.02% | +266.7% |
| Q4 2016 | $245,000 | -62.4% | 12,966 | -40.2% | 0.01% | -57.1% |
| Q3 2016 | $651,000 | -66.9% | 21,683 | -57.7% | 0.01% | -58.8% |
| Q2 2016 | $1,968,000 | +17.4% | 51,200 | +16.4% | 0.03% | +13.3% |
| Q1 2016 | $1,676,000 | +61.5% | 44,000 | +86.4% | 0.03% | +172.7% |
| Q4 2015 | $1,038,000 | -39.4% | 23,600 | -43.9% | 0.01% | -31.2% |
| Q3 2015 | $1,713,000 | -32.7% | 42,100 | -11.8% | 0.02% | -30.4% |
| Q2 2015 | $2,545,000 | – | 47,713 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |